BCR-ABL
Cepheid Developing New Target for BCR-ABL Test for Leukemia Patients
The firm's new application of its BCR-ABL test will be able to detect p190 transcripts and is currently for research use only.
Cepheid Xpert BCR-ABL Ultra Leukemia Monitoring Test Gets FDA Clearance
The in vitro diagnostic test can deliver molecular results from whole blood samples in less than three hours, the company said.
Health Canada Approves Two BCR-ABL Tests
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
MolecularMD, Genoptix Ink Marketing Agreement for CDx to Novartis CML Drug
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
Asuragen Gets CE Mark for QuantideX BCR-ABL Kits on Roche Platform
Asuragen test kits to detect major and minor BCR-ABL fusions can now run on the Roche Diagnostics Cobas z 480 Analyzer.